Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 264-265

  Woll, P J ^a,h   Basser, R ^b   Le Chevalier, T ^c   Drings, P ^d   Perez Manga G ^e   Adenis, A ^f   Seymour, L ^g   Smith, F ^g   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WESTERN HOSPITAL   (Australia)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Institute of Medical Oncology   (Germany)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f CENTRE OSCAR LAMBRET   (France)

^g ASTRAZENECA   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Phase II study; Raltitrexed; Small cell lung cancer; Thymidylate synthase inhibitor; Tomudex; ZD1694

Indexed keywords

RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0031011302     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.373     Document Type: Article

References (9)

1. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman A, Hughes LR, Harrap KR, Kennealey GT and Judson IR (1996) Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14: 1495-1503
2. Cullen M (1989) The design of phase II trials. Lung Cancer 5: 214-220
3. Cunningham D, Zalcberg J, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K and the 'Tomudex' Colorectal Cancer Study Group (1995) 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A: 1945-1954
4. Cunningham D, Zalcberg J, Smith J. Gore M, Pazdur R, Burris H, Meropol NJ, Kennealey G, Seymour L and the 'Tomudex' International Study Group (1996) 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 7: 179-182
5. Ettinger DS (1990) Evaluation of new drugs in untreated patients with small cell lung cancer - its time has come. J Clin Oncol 8: 374-377
6. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Culvert H, Judson IR and Hughes LR (1991) ICI D1694, a quinazoline antilblate thymidylate synthase inhibitor that is a potent inhibitor of LI210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579-5586
7. Moore TD and Korn EL (1992) Phase II trial design considerations for small cell lung cancer. J Natl Cancer Inst 84: 150-154
8. Parker SL, Tong T, Bolden S and Wingo PA (1996) Cancer statistics, 1996. CA Cancer J Clin 65: 5-27
9. Sorensen JM, Jordan E, Grem JL et al (1994) Phase I trial of the new thymidylate synthase inhibitor 'Tomudex' (ZD1694) in patients with advanced malignancy (abstract 240). Ann Oncol 5 (suppl. 5): 132